US woes lead Teva to a further US$11bn charge
Teva has registered a goodwill impairment of US$11.0 billion for the fourth quarter of 2017, “mainly related to our US generics reporting unit”, following continued “challenging market dynamics” in the region. The impairment comes on top of a US$6.1 billion goodwill impairment in the second quarter of 2017 (Generics bulletin, 11 August 2017, page 1), resulting in a US$17.1 billion total goodwill impairment for 2017. As a result, the company reported an annual US$17.5 billion operating loss on sales up by 2% to US$22.4 billion.
You may also be interested in...
Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.